

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM669164

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Goldman Sach Bank USA		08/19/2021	Chartered Bank: NEW YORK
RECEIVING PARTY DATA			
Name:	Azurity Pharmaceuticals, Inc.		
Street Address:	8 Cabot Road		
Internal Address:	Suite 2000		
City:	Woburn		
State/Country:	MASSACHUSETTS		
Postal Code:	01801		
Entity Type:	Corporation: DELAWARE		
Name:	Silvergate Pharmaceuticals, Inc.		
Street Address:	8 Cabot Road		
Internal Address:	Suite 2300		
City:	Raleigh		
State/Country:	NORTH CAROLINA		
Postal Code:	01801		
Entity Type:	Corporation: DELAWARE		
Name:	Argentum Holdings, LLC		
Street Address:	1717 Saint James Place		
Internal Address:	Suite 660		
City:	Houston		
State/Country:	TEXAS		
Postal Code:	77056		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 4			
Property Type	Number	Word Mark	
Registration Number:	5651067	FIRVANQ	
Registration Number:	5525903	FIRVANQ	
Registration Number:	5498187	RXM THERAPEUTICS	
Registration Number:	5623056	RXM THERAPEUTICS	

CH \$115.00 5651067

CORRESPONDENCE DATA**Fax Number:** 9198216800*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.***Phone:** (919) 838-2034**Email:** pkarmire@smithlaw.com**Correspondent Name:** Perky L. Karmire / Smith Anderson Law**Address Line 1:** 150 Fayetteville Street**Address Line 2:** Suite 2300**Address Line 4:** Raleigh, NORTH CAROLINA 27602

NAME OF SUBMITTER:	Perky L. Karmire
SIGNATURE:	/s/ Perky L. Karmire
DATE SIGNED:	08/20/2021

Total Attachments: 3

source=Goldman Sachs - USPTO TMSA Termination of 5.17.19 - Azurity#page1.tif

source=Goldman Sachs - USPTO TMSA Termination of 5.17.19 - Azurity#page2.tif

source=Goldman Sachs - USPTO TMSA Termination of 5.17.19 - Azurity#page3.tif

**TERMINATION AND RELEASE
OF
INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT (“Termination and Release”) dated as of August 19, 2021, is made by Goldman Sachs Bank USA, as Collateral Agent (“Grantee”), in favor of Azurity Pharmaceuticals, Inc., Silvergate Pharmaceuticals, Inc., and Argentum Holdings, LLC (“Grantors”). Capitalized terms used in this Termination and Release and not otherwise defined herein have the meanings specified in the Intellectual Property Security Agreement (defined below).

WITNESSETH:

WHEREAS, pursuant to that certain Trademark Security Agreement dated as of May 17, 2019, by and between Grantors and Grantee, Grantors executed that certain Intellectual Property Security Agreement in United States Trademarks, effective as of May 17, 2019 (the “Trademark Security Agreement”), which was recorded in the United States Patent and Trademark Office on May 17, 2019 at Reel 006651/Frame 0782, pursuant to which Grantors granted a security interest to Lenders in Grantors’ Trademarks, including certain trademarks and/or trademark applications listed on Exhibit A attached hereto and made a part hereof.

WHEREAS, pursuant to Grantor’s name change, effective as of January 22, 2020, Grantor filed a Change of Name with the United State Patent and Trademark Office which was recorded in the United States Patent and Trademark Office on April 21, 2020 at Reel 006919 / Frame 0944, pursuant to which Grantor granted a security interest to Lenders in Grantor’s Trademarks, including certain trademarks and/or trademark applications listed on Exhibit A attached hereto and made a part hereof.

WHEREAS, Grantee now desires to terminate and release its security interest in the Trademarks listed on Exhibit A attached hereto and reassign any and all rights, title, and interest in the same to Grantors;

NOW, THEREFORE, for good and valuable consideration, receipt and sufficiency of which are hereby acknowledged:

1. Grantee hereby releases its security interest in all of Grantors’ right, title and interest in and to the Trademarks set forth on Exhibit A.
2. If and to the extent that Grantee has acquired any right, title or interest in or to any of the Trademarks set forth on Exhibit A, Grantee hereby reassigns, grants and conveys to Grantors, without any representation, warranty, recourse or undertaking by Grantee, any and all of Grantee’s right, title, and interest in and to such Trademarks.

[signature page follows]

IN WITNESS WHEREOF, Grantee has caused this Termination and Release to be duly executed and delivered as of the date first written above.

GOLDMAN SACHS BANK USA, AS
COLLATERAL AGENT

By: _____
Name: _____
Title: _____



Greg Watts
Authorized Signatory

[Signature Page to Trademark Security Agreement Release (Goldman Sachs)]

TRADEMARK
REEL: 007399 FRAME: 0183

EXHIBIT A

U.S. Trademark Registrations/Applications

OWNER	TRADEMARK	APPLICATION NUMBER / REGISTRATION NUMBER	APPLICATION DATE / REGISTRATION DATE
AZURITY PHARMACEUTICALS, INC.	 FIRVANQ	87715534 5651067	12/11/17 1/8/19
AZURITY PHARMACEUTICALS, INC.	FIRVANQ	87451656 5525903	5/16/17 7/24/18
AZURITY PHARMACEUTICALS, INC.	RXM THERAPEUTICS	86749911 5498187	9/8/15 6/19/18
AZURITY PHARMACEUTICALS, INC.	 RXM THERAPEUTICS	86749943 5623056	9/8/15 12/4/18